Aurinia Pharmaceuticals announced the start of a rolling submission of its application requesting that voclosporin be approved in the U.S. to treat people with lupus nephritis. In a rolling submission, completed portions of a New Drug Application (NDA) are submitted for review by the U.S. Food and Drug Administration…
PRV-3279, a potential therapy for people with systemic lupus erythematosus (SLE), durably blocks B-cells to prevent them from producing damaging antibodies, but does not deplete these key immune defense system cells, results from the first part of a Phase 1b/2 trial show. The Phase 1b portion of the PREVAIL study (…
Aurinia Pharmaceuticals is again partnering with the National Kidney Foundation (NFK) during National Kidney Month to raise awareness of lupus nephritis (LN) — a type of kidney disease caused by systemic lupus erythematosus, or lupus. A new program launched by Aurinia, called ALL IN, is an online…
Treatment with Acthar Gel (repository corticotropin injection) may ease exacerbations and symptoms in people with systemic lupus erythematosus (SLE) and other inflammatory disorders, a real-world study reports. About 95% of those with SLE showed benefits, as rated by physicians. The study, “…
Taking into account patient-reported lupus flares in clinical practice may help assess disease severity and the economic impact of the disease, including loss of work productivity and hospital care, according to a recent study. Current measurements of flares do not include a patient’s own perspective. That…
Lower income is associated with a significantly higher risk of certain kidney diseases, including lupus nephritis, a new study found. The study, “Socioeconomic Position and Incidence of Glomerular Diseases,” was published in the Clinical Journal of American Society of Nephrology. How much money individuals have can…
In recognition of Rare Disease Day Feb. 29, Bionews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the #WhatMakesMeRare campaign was aimed at uplifting people with rare diseases by encouraging them to share their stories and perspectives. The…
An educational program done in small, local, and peer-led groups, called the Chronic Disease Self‐Management Program, was seen as helpful by African-American women with systemic lupus erythematosus (SLE), improving their diet, ability to exercise, and their adherence to treatment, a study suggests. The study, “Exploring…
More stringent thresholds in the Cutaneous Lupus Activity and Severity Index (CLASI), a common tool to assess disease progression and treatment response in cutaneous lupus erythematosus (CLE), can better identify patients with clinical improvements, a study reports. Its findings also suggest that people who develop CLE early in…
Enzo Biochem’s investigational compound SK1‑I lessened autoimmune and inflammatory responses, including in the kidney, in a mouse model of systemic lupus erythematosus lupus (SLE). SK1-I was beneficial when given to mice not only before but also after disease onset, providing evidence that it may be a potential effective…